5 results match your criteria: "Provincial Multi-Specialized Oncology and Trauma Center[Affiliation]"
Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk.
Cancers (Basel)
November 2024
Department of Hematooncology, Provincial Multi-Specialized Oncology and Trauma Center, 93-513 Lodz, Poland.
Article Synopsis
- Daratumumab (Dara) is the first monoclonal antibody used to treat multiple myeloma (MM), showing effectiveness but also an increased risk of infectious complications (ICs) during treatment.
- A study reviewed data from 139 MM patients treated with Dara from July 2019 to March 2024, finding that 39.6% experienced ICs, primarily pneumonia and upper respiratory infections, with some patients facing severe complications requiring hospitalization.
- Predictive models using various algorithms were developed to identify factors influencing severe ICs, highlighting the importance of hemoglobin levels and performance status in determining patient risk during treatment.
Characteristics and outcomes of patients with lymphoma who developed therapy-related acute myeloid leukemia or myelodysplastic syndrome - a retrospective analysis of the Polish Adult Leukemia Group.
Contemp Oncol (Pozn)
July 2024
Hematology Department, Medical University of Łódź, Łódź, Poland.
Article Synopsis
- The study focuses on the increased risk of developing therapy-related acute myeloid leukemia (t-AML) and myelodysplastic syndrome (t-MDS) after lymphoma treatment, examining patient outcomes and prognostic factors.* -
- Conducted over seven centers in Poland from 2011 to 2018, the analysis included 57 patients with a median age of 65, revealing a median overall survival of 16.1 months and a time to t-MDS/AML onset of about 58.7 months.* -
- Key independent prognostic factors for survival included unfavorable cytogenetics, hemoglobin levels, and platelet counts, emphasizing that anemia and low platelet counts may signal more severe bone marrow dysfunction,
High Serum miR-361-3p Predicts Early Postdischarge Infections after Autologous Stem Cell Transplantation.
Infect Chemother
September 2024
Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Background: Autologous hematopoietic stem cell transplantation (AHSCT) is currently the backbone of the treatment of multiple myeloma (MM) and relapsed and refractory lymphomas. Notably, infections contribute to over 25% of fatalities among AHSCT recipients within the initial 100 days following the procedure. In this study, we aimed to evaluate three selected miRNAs: hsa-miR-155-5p, hsa-miR-320c, and hsa-miR-361-3p, in identifying AHSCT recipients at high risk of infectious events up to 100 days post-transplantation after discharge.
View Article and Find Full Text PDFA hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.
Front Oncol
May 2024
Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Introduction: Mixed-phenotype acute leukemia (MPAL) is a rare disease with poor prognosis. So far, no standard approach has been established as the "know-how" of MPAL is based only on retrospective analyses performed on small groups of patients.
Materials And Methods: In this study, a retrospective analysis of the outcomes of adult MPAL patients included in the PALG registry between 2005 and 2024 who received the CLAG-M hybrid protocol as induction or salvage therapy was performed.
MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation.
Biomark Res
April 2024
Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Autologous hematopoietic stem cell transplantation (AHSCT) remains the most prevalent type of stem cell transplantation. In our study, we investigated the changes in circulating miRNAs in AHSCT recipients and their potential to predict early procedure-related complications. We collected serum samples from 77 patients, including 54 with multiple myeloma, at four key time points: before AHSCT, on the day of transplantation (day 0), and at days + 7 and + 14 post-transplantation.
View Article and Find Full Text PDF